Reference for VIRALYTICS. Search for VIRALYTICS

AI searches containing VIRALYTICS

VIRALYTICS

Viralytics

Biotechnology company

process to Viralytics to reflect the fact that oncolytic viruses were now its core focus. Shafren's wild-type Coxsackievirus A21, which Viralytics called

Viralytics

Merck & Co.

American multinational pharmaceutical company

a professional in Melbourne, Australia. In June 2018, Merck acquired Viralytics, an Australian viral cancer drug company, for AUD$502 million. In 2018

Merck & Co.

Merck_&_Co.

Paul A. Hopper

Australian bioentrepreneur (born 1956)

December 2015. "Viralytics restructures Board and Management" (PDF). asx.com.au. 23 October 2008. Retrieved 3 December 2015. "MSD and Viralytics Announce Acquisition

Paul A. Hopper

Paul_A._Hopper

ICAM-1

Mammalian protein found in Homo sapiens

Coxsackievirus A21, an oncolytic virus (brand name Cavatak, being developed by Viralytics). Cannabinoid CB2 receptor agonists have been found to decrease the induction

ICAM-1

Oncolytic virus

Type of virus

is being tested clinically. Coxsackievirus A21 is being developed by Viralytics under trade name Cavatak. Coxsackievirus A21 belongs to Enterovirus C

Oncolytic virus

Oncolytic_virus

Murine respirovirus

Sendai virus, virus of rodents

non-pathogenic Sendai virus", issued 27 December 2016, assigned to Sendai Viralytics LLC Kiyohara E, Tanemura A, Nishioka M, Yamada M, Tanaka A, Yokomi A

Murine respirovirus